Mary H. H. Ensom
BS(Pharm), PharmD, FASHP, FCCP, FCSHP, FCAHS
Dr. Ensom earned her BS(Pharm) degree in 1977 and PharmD in 1985, both from the University of Kentucky (UK). In between degrees, she was a hospital pharmacist and developed clinical services in South Carolina, Washington, and Kentucky. She completed a postdoctoral fellowship in clinical pharmacokinetics at UK in 1987, served on the faculty at the UK College of Pharmacy and as director of the Clinical Pharmacokinetics Service at the UK Chandler Medical Center for 10 years (1987–97) before joining the Faculty at UBC in 1997 where she served as director of the UBC Graduate PharmD program for 10 years (2002–12).
Dr. Ensom has 536 publications (including 258 articles in peer-reviewed journals, 226 research abstracts, four books/monographs, 15 book chapters, and over 30 other works) to her credit. Aside from PharmD students, she has supervised and co-supervised over 100 hospital pharmacy residents, MSc students, PhD students, and postdoctoral fellows.
Dr. Ensom has received more than 80 awards for scholarship, research, and service, including 10 outstanding teacher awards. She is one of only 34 distinguished university scholars at UBC. In addition, Dr. Ensom is the only Canada-based recipient of the Education or Publication Award from the American College of Clinical Pharmacy (ACCP), a U.S.-based international organization with more than 15,000 members. She is the only Canada-based recipient of the Award for Sustained Contributions to the Literature from the American Society of Health-System Pharmacists (ASHP), a 40,000 plus member, U.S.-based international organization. She is an elected ACCP Research Institute Trustee, recipient of the Paul F. Parker Award from the UK Pharmacy Residency Program for "an individual who has displayed sustained contribution to the profession in practice, teaching or research; a commitment to high ideals and excellence in their chosen field; leadership and innovation; and a passion to encourage the personal and professional growth of others," and member of the inaugural class (n=4) of the Hall of Distinguished Alumni, UK College of Pharmacy.
Dr. Ensom was editor for the Canadian Journal of Hospital Pharmacy for 10 years and serves on the editorial boards of five other journals. She is a fellow of ASHP, ACCP, and the Canadian Society of Hospital Pharmacists (CSHP), and the Canadian Academy of Health Sciences (CAHS).
What distinguishes Dr. Ensom's translational (bedside to bench to bedside) research program from most others' in the Faculty is that it is both clinical and laboratory-based. Dr. Ensom's long-term research focus has been in clinical pharmacokinetics and pharmacodynamics (particularly as these disciplines relate to: women's health; effects of gender, age, and other pathophysiologic states on pharmacokinetics and pharmacodynamics; and novel approaches to therapeutic drug monitoring), with more recent interests in pharmacogenetics and pharmaceutical outcomes evaluations.
Every day, Dr. Ensom uses her clinical practice experiences to identify relevant pharmacokinetic/pharmacodynamic/ pharmacogenetic problems that are then studied in the laboratory. As such, her research teams (specific for each project) consist of clinicians, laboratory scientists, and a full array of trainees (BSc, MSc, PharmD, and PhD students; pharmacy residents; and postdoctoral fellows).
As an integrator who bridges the gap between the basic and clinical sciences, the goal of Dr. Ensom's translational research program is to address clinical problems from a qualitative, quantitative, and mechanistic perspective and to make a difference in the health and well-being of patients (i.e., study results are directly and immediately incorporated into patient care).
Her research program has received more than 140 government, foundation, and industry grants totaling more than $7 million. Current projects include:
Immunosuppressant Pharmacokinetics, Limited Sampling Strategies, and Pharmacogenetics
Characterizes the pharmacokinetics of (and develop limited sampling strategies for) mycophenolate and tacrolimus in lung, heart, kidney, and islet transplant recipients and ascertains the contribution of genetic polymorphisms (e.g., UGT and ABCC2) and other factors to inter-patient variability in pharmacokinetics of mycophenolate and its glucuronidated metabolites.
Impact of Various Pathophysiologic Conditions on Pharmacokinetics and Pharmacodynamics
Evaluates the pharmacokinetics/pharmacodynamics of various drugs in patients with various pathophysiologic conditions (e.g., intravenous immunoglobulin in patients with recurrent pregnancy loss, prior to and during pregnancy, and in patients with other immunologic conditions).
Stability of Medications in Extemporaneously Prepared Formulations for Use in Pediatric and Other Patients
Evaluates the stability of various extemporaneously-compounded oral and intravenous formulations and apply the results immediately to care of pediatric and other patients.
Dr. Ensom is also contributing to various other pharmacokinetics/pharmacodynamics/pharmacogenetics, and pharmaceutical outcomes studies as co-investigator.
"2015 Inaugural Class (n=4) of Hall of Distinguished Alumni." Ensom MHH. University of Kentucky College of Pharmacy. March 2015.
"The 2012 ASHP Foundation's Award for Sustained Contributions for significant contributions to the biomedical literature." Ensom MHH. American Society of Health-System Pharmacists (ASHP). December 2012.
"The 2011 ACCP Education Award for major contributions to advancing clinical pharmacy education." Ensom MHH. American College of Clinical Pharmacy (ACCP). October 2011.
"2007 UBC Killam Research Prize (in Science Category) (n=5)." Ensom MHH. UBC. February 2008.
"The 2006 ACCP Russell R Miller Publication Award in recognition of sustained and outstanding contributions to the literature of clinical pharmacy." Ensom MHH. ACCP. October 2006.
"Stability of Extemporaneously Compounded Suspensions." Ensom MHH (PI), Decarie D. $80,000. Medisca Pharmaceutique Inc. 2013–2015.
"Pharmacokinetics and Pharmacogenetics of Mycophenolate: Prediction of Neutropenia in Steroid-Free Renal Transplant Recipients." Ensom MHH (PI), Shapiro RJ, Partovi N, Kiang TKL, Guillemette C. $40,000. Hoffman La-Roche Ltd. 2011–2015.
"Microneedle-based Painless Drug Monitoring System in Interstitial Fluid." Hafeli U (PI), Ensom MHH (co-PI), Stoeber B. $374,014. NSERC/CIHR Collaborative Health Research Projects Program (CHRP). 2010–2013.
"Stability of Propranolol in Extemporaneously Compounded Suspensions: New Formulations for an Old Drug." Ensom MHH (PI), Kendrick J, Rudolph S, Decarie D. $10,000. Canadian Society of Hospital Pharmacists. 2012.
"Pharmacogenetics of Mycophenolate in Thoracic Transplant Recipients: Role of UDP-Glucuronosyltransferase Genetic Polymorphisms." Ensom MHH (PI), Guillemette C, Partovi N, Riggs KW, Levy RD. $286,929. CIHR. 2005–2008.
"Debates in the Teaching and Practice of Clinical Pharmacokinetics and Pharmacogenetics." Ensom MHH. American College of Clinical Pharmacy 2014 Annual Meeting. Austin, TX. December 2014.
"Putting Pharmacogenetics to Practice: Real-Time Examples." Ensom MHH. Canadian Society of Hospital Pharmacists - BC Branch Spring Therapeutics Update 2014. Vancouver, BC. April 2014.
"Drug Dosing in Obese Patients." Ensom MHH. CSHP 66th Summer Educational Sessions. Calgary, AB. August 2013.
"Evidence Based Approaches to Pharmacokinetic Dilemmas: The best size descriptor for drug dosing in obese patients is not ideal body weight as determined by the Devine method." Ensom MHH. American Society of Health-System Pharmacists 46th Midyear Clinical Meeting. Las Vegas, NV. December 2012.
"Development and Validation of Limited Sampling Strategies for Tacrolimus and Mycophenolate in Steroid-Free Renal Transplant Regimens." Ensom MHH. American College of Clinical Pharmacy 2010 Annual Meeting. Austin, TX. October 2010.